Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Phase 2 Completed
266 enrolled 15 charts
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
Phase 3 Completed
729 enrolled 14 charts
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Phase 1 Completed
24 enrolled 26 charts
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
Phase 4 Completed
485 enrolled 17 charts
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
Phase 1 Completed
27 enrolled
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
Phase 3 Completed
200 enrolled 16 charts
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
Phase 1/2 Completed
37 enrolled
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
Phase 1 Completed
79 enrolled
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
Phase 2 Completed
40 enrolled
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Phase 4 Completed
502 enrolled
MIKADO
Completed
1,218 enrolled
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
Phase 4 Completed
20 enrolled 12 charts
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Phase 3 Completed
519 enrolled 11 charts
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
Phase 3 Completed
469 enrolled 10 charts
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
Phase 3 Completed
441 enrolled 9 charts
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
Phase 3 Completed
507 enrolled 11 charts
Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
Completed
840 enrolled
RAPID-ACT
Completed
1,168 enrolled
PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed
1,324 enrolled
Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy
Phase 4 Completed
50 enrolled
PrAKtice
Completed
440 enrolled
Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin
Phase NA Completed
23 enrolled
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
Phase 1 Completed
16 enrolled
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
Phase 4 Completed
16 enrolled 5 charts
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
Phase 2 Completed
200 enrolled
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
Phase 2 Completed
50 enrolled
A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Phase 1 Completed
50 enrolled
A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers
Phase 1 Completed
30 enrolled
A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)
Phase 3 Completed
102 enrolled
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
Phase 2 Completed
12 enrolled
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Phase 3 Completed
269 enrolled 9 charts
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
Phase 2 Completed
60 enrolled
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
Phase 2 Completed
34 enrolled
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Phase 3 Completed
255 enrolled 9 charts
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
Phase 2 Completed
16 enrolled 9 charts
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Phase 3 Completed
278 enrolled 9 charts
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Phase 3 Completed
203 enrolled 8 charts
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
Phase 1 Completed
8 enrolled
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Phase 2 Completed
60 enrolled
Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis
Phase NA Completed
100 enrolled
Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp
Phase 1 Completed
20 enrolled
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis
Phase 2 Completed
24 enrolled
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Phase 2 Completed
60 enrolled